175.58
price up icon2.37%   4.06
 
loading
Abbvie Inc stock is traded at $175.58, with a volume of 12.92M. It is up +2.37% in the last 24 hours and up +4.66% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$171.52
Open:
$171.794
24h Volume:
12.92M
Relative Volume:
2.28
Market Cap:
$310.27B
Revenue:
$55.53B
Net Income/Loss:
$5.12B
P/E Ratio:
48.10
EPS:
3.65
Net Cash Flow:
$15.62B
1W Performance:
+1.27%
1M Performance:
+4.66%
6M Performance:
+2.00%
1Y Performance:
+15.75%
1-Day Range:
Value
$170.66
$176.80
1-Week Range:
Value
$170.21
$176.80
52-Week Range:
Value
$151.29
$207.32

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
50,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
175.58 310.27B 55.53B 5.12B 15.62B 2.88
Drug Manufacturers - General icon
LLY
Lilly Eli Co
767.76 690.46B 40.86B 8.37B -2.28B 9.25
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
85.00 377.54B 39.36B 13.79B 9.83B 3.086
Drug Manufacturers - General icon
JNJ
Johnson Johnson
144.47 347.83B 87.70B 14.68B 19.03B 6.05
Drug Manufacturers - General icon
MRK
Merck Co Inc
98.05 248.03B 63.17B 12.15B 14.84B 4.77

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
Dec 20, 2024

Abbvie - Contract Pharma

Dec 20, 2024
pulisher
Dec 20, 2024

AbbVie (NYSE:ABBV) Stock Price Up 2%Here's What Happened - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

AbbVie, Novartis and drug industry win court battle in larger 340B war - Crain's Chicago Business

Dec 20, 2024
pulisher
Dec 20, 2024

Alembic Pharma Gains USFDA Approval for Epilepsy Treatment - Devdiscourse

Dec 20, 2024
pulisher
Dec 20, 2024

GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News

Dec 20, 2024
pulisher
Dec 19, 2024

AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Dec 19, 2024
pulisher
Dec 19, 2024

AI & Data Convergence - AbbVie

Dec 19, 2024
pulisher
Dec 19, 2024

AbbVie (NYSE:ABBV) Trading Down 0.5% After Insider Selling - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

AbbVie acquiring Madison-based Nimble Therapeutics for $200 million - Milwaukee Journal Sentinel

Dec 19, 2024
pulisher
Dec 19, 2024

AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline - Kilgore News Herald

Dec 19, 2024
pulisher
Dec 19, 2024

Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now? - Insider Monkey

Dec 19, 2024
pulisher
Dec 19, 2024

Acellular Dermal Matrices Market Projected To Witness Substantial Growth, 2024-2031: Stryker Corporation, - EIN News

Dec 19, 2024
pulisher
Dec 18, 2024

Abbvie SVP Kevin Buckbee sells stock for $310,032 - Investing.com India

Dec 18, 2024
pulisher
Dec 18, 2024

Kevin K. Buckbee Sells 1,800 Shares of AbbVie Inc. (NYSE:ABBV) Stock - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL - Citeline News & Insights

Dec 18, 2024
pulisher
Dec 18, 2024

AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Dec 18, 2024
pulisher
Dec 18, 2024

Novartis, AbbVie Score Win to Block West Virginia Drug Limit Law - Bloomberg Law

Dec 18, 2024
pulisher
Dec 18, 2024

AbbVie's SWOT analysis: biopharma giant navigates post-Humira landscape - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance

Dec 18, 2024
pulisher
Dec 18, 2024

AbbVie Inc. (NYSE:ABBV) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Biologics Market to See Booming Growth 2024-2031 | AbbVie Inc., - openPR

Dec 18, 2024
pulisher
Dec 17, 2024

AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch

Dec 17, 2024
pulisher
Dec 17, 2024

AbbVie's (ABBV) Overweight Rating Reiterated at Piper Sandler Companies - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

Bain Sued Over Cerevel Trades Before $8.7 Billion Sale to AbbVie - Bloomberg Law

Dec 17, 2024
pulisher
Dec 17, 2024

AbbVie (NYSE:ABBV) Price Target Raised to $220.00 at Piper Sandler - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

4 Big Drug Stocks That May Continue to Outperform in 2025 - Yahoo Finance

Dec 17, 2024
pulisher
Dec 17, 2024

AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? - Yahoo! Voices

Dec 17, 2024
pulisher
Dec 17, 2024

Spinal Cord Injury Therapeutics Market Set to Witness Significant Growth by 2024-2031: AbbVie Inc, Pfizer - EIN News

Dec 17, 2024
pulisher
Dec 17, 2024

Immunology Market Huge Growth in Future Scope 2024-2031 | AbbVie - openPR

Dec 17, 2024
pulisher
Dec 17, 2024

Is AbbVie Ready for a Bullish Turn? - Investing.com

Dec 17, 2024
pulisher
Dec 17, 2024

Is AbbVie Ready for a Bullish Turn? - Investing.com

Dec 17, 2024
pulisher
Dec 17, 2024

Botulinum Toxin in Urology Market Top PlayersAbbVie Inc., Merz Pharma; Ipsen Pharma; GALDERMA; Allergan PLC. - openPR

Dec 17, 2024
pulisher
Dec 16, 2024

AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish - MSN

Dec 16, 2024
pulisher
Dec 16, 2024

AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Dec 16, 2024
pulisher
Dec 16, 2024

Why Investors Should Watch AbbVie Inc (ABBV) - See It Market

Dec 16, 2024
pulisher
Dec 16, 2024

AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors - Seeking Alpha

Dec 16, 2024
pulisher
Dec 16, 2024

AbbVie (ABBV) Acquires Nimble Therapeutics for $200 Million - GuruFocus.com

Dec 16, 2024
pulisher
Dec 16, 2024

AbbVie Enters Oversold Territory - Forbes

Dec 16, 2024
pulisher
Dec 16, 2024

AbbVie, Novartis Drop Suit Over Kansas Drug Discount Limit Law - Bloomberg Law

Dec 16, 2024
pulisher
Dec 16, 2024

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline - Yahoo Finance

Dec 16, 2024
pulisher
Dec 16, 2024

AbbVie continues deal-making spree with $200M Nimble buy - PharmaLive

Dec 16, 2024
pulisher
Dec 16, 2024

AbbVie Continues Deal-Making Spree With $200M Nimble Buy - BioSpace

Dec 16, 2024
pulisher
Dec 16, 2024

AbbVie adds psoriasis med with Nimble takeover - pharmaphorum

Dec 16, 2024
pulisher
Dec 16, 2024

AbbVie to acquire Nimble Therapeutics for $200m - Yahoo Finance

Dec 16, 2024
pulisher
Dec 16, 2024

Alzheimers Drugs Market to See Booming Growth 2024-2031 | - openPR

Dec 16, 2024
pulisher
Dec 15, 2024

AbbVie to acquire Nimble Therapeutics in $200m deal - World Pharmaceutical Frontiers

Dec 15, 2024
pulisher
Dec 15, 2024

AbbVie Parkinson’s Drug Rejected by FDA After Plant Inspection - MSN

Dec 15, 2024
pulisher
Dec 14, 2024

AbbVie Inc. (NYSE:ABBV) Stock Position Lowered by Lord Abbett & CO. LLC - MarketBeat

Dec 14, 2024
pulisher
Dec 14, 2024

B. Riley Wealth Advisors Inc. Decreases Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat

Dec 14, 2024
pulisher
Dec 13, 2024

AbbVie (ABBV) Announces Leadership Transition in Financial Department - GuruFocus.com

Dec 13, 2024
pulisher
Dec 13, 2024

AbbVie nabs autoimmune diseases specialist Nimble - The Pharma Letter

Dec 13, 2024

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$144.47
price up icon 0.62%
drug_manufacturers_general MRK
$98.05
price down icon 1.48%
drug_manufacturers_general NVO
$85.00
price down icon 17.83%
drug_manufacturers_general NVS
$97.11
price up icon 0.35%
drug_manufacturers_general PFE
$26.36
price up icon 2.29%
Cap:     |  Volume (24h):